183170-69-6 Usage
General Description
Tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate is a chemical compound with a molecular structure consisting of a tert-butyl group, a piperidine ring, and a carboxylate functional group. tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate is a ester derivative of piperidine, and its hydroxyethyl substituent makes it a potentially important intermediate in the synthesis of certain pharmaceuticals or other organic compounds. The tert-butyl group provides steric hindrance, making the compound more stable and less reactive. The presence of the hydroxyethyl group adds hydrophilic properties to the compound, making it potentially useful in drug formulation. These properties make tert-butyl 4-(1-hydroxyethyl)piperidine-1-carboxylate a versatile compound with potential applications in various chemical and pharmaceutical industries.
Check Digit Verification of cas no
The CAS Registry Mumber 183170-69-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,3,1,7 and 0 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 183170-69:
(8*1)+(7*8)+(6*3)+(5*1)+(4*7)+(3*0)+(2*6)+(1*9)=136
136 % 10 = 6
So 183170-69-6 is a valid CAS Registry Number.
183170-69-6Relevant articles and documents
ATF6 MODULATORS AND USES THEREOF
-
, (2021/04/17)
Compounds (1-2) as modulators of Activating Transcription Factor 6 (ATF6) are provided. The compounds may find use as therapeutic agents for the treatment of diseases or disorders mediated by ATF6 and may find particular use in the treatment of viral infections, neurodegenerative diseases, vascular diseases, or cancer. (Formula (1-2))
NOVEL COMPOUNDS AS GPR119 AGONISTS
-
Paragraph 0308; 0309, (2017/10/26)
The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
GPR119 Agonists
-
Page/Page column 6, (2011/02/18)
GPR119 agonist compounds of the formula: and pharmaceutical compositions for the treatment of diabetes and obesity.